Agree with you. Like some others I really didn’t get much from today’s PR. I would have liked more concrete dates or at least better guidance than…”statistician team is currently analyzing the Data and the Company aims to submit the amended Study protocol to the FDA shortly thereafter”
I understand they can’t control the pace of FDA but I would think they can control the pace of their own analysis.
Obviously we want the analysis thoroughly done but I think some guardrails on timing is still possible. Oh well…we wait some more. Fingers crossed.
Did i say anything about setting "definitive" deadlines, and if so could you kindly point it out?
Make your point without making up tales.
Last i checked the stst team was independent ie not employees of revive so again it boils down to mf probably not wanting to make any claims that may or may not materialize.
Apparently the typical modus operandi of otc pinks ceos is more to your liking.
News 
Market Data 
Discover 
